Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Frédéric Millot, MD, Andre Baruchel, MD, Joelle Guilhot, BS, Arnaud Petit, MD, Thierry Leblanc, MD, Yves Bertrand, MD, Françoise Mazingue, Lutz Patrick, MD, Cécile Vérité, MD, Christian Berthoux, MD, Claire Galambrun, MD, Frédéric Bernard, MD, Karima Yacouben, MD, Pierre Bordigoni, Pr, Christine Edan, MD, Yves Reguerre, MD, Gérard Couillaud, MD, Jean-Michel Cayuela, MD, François Guilhot, MD

Blood (2009) 114 (22): 863.

https://doi.org/10.1182/blood.V114.22.863.863

Published: 2009

Journal Articles

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Francois Guilhot, MD, Lydia Roy, MD, Joelle Guilhot, BS, Tillmann Krahnke, BSR, Agnes Guerci, MD, Brian Druker, MD, Richard Larson, MD, Steve O’Brien, MD, Charlene So, PharmD, Giorgio Massimini, MD

Blood (2005) 106 (11): 165.

https://doi.org/10.1182/blood.V106.11.165.165

Published: 2005

Journal Articles

Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.

Agnès Guerci, MD, Franck Nicolini, MD, Frederic Maloisel, MD, Selim Corm, MD, Laurence Legros, MD, Françoise Rigal-Huguet, MD, Philippe Rousselot, MD, Krimo Bouabdallah, MD, Martine Gardembas, MD, Anne Vekoff, MD, Jean-Jacques Kiladjian, MD, Martine Delain, MD, François-Xavier Mahon, MD, Claude Preudhomme, MD, Joelle Guilhot, BS, François Guilhot, MD

Blood (2005) 106 (11): 168.

https://doi.org/10.1182/blood.V106.11.168.168

Published: 2005

Journal Articles

Results of a Phase II Trial Testing Interferon Alpha 2b and Cytarabine in Children with Chronic Myelogenous Leukemia.

Frédéric Millot, MD, Joelle Guilhot, BS, Brigitte Nelken, MD, Jean-Pierre Lamagnère, MD, Thierry Leblanc, MD, Guy Leverger, MD, Anne Notz, MD, Dominique Plantaz, MD, Frédéric Bernard, MD, Pierre Bordigoni, MD, Karima Yacouben, MD, Catherine Behar, MD, Antoine Thyss, MD, Cornu Guy, MD, Sylvain Duchène, MD, François Guilhot, MD

Blood (2004) 104 (11): 1000.

https://doi.org/10.1182/blood.V104.11.1000.1000

Published: 2004

Journal Articles

A Phase I/II Dose Escalating Study of Daunorubicin Combined with Imatinib Mesylate and Cytarabine as Induction Therapy for Chronic Myelogenous Leukaemia in Myeloid Blast Crisis. Preliminary Results of the AFR01 Trial.

Philippe Rousselot, MD, Laurence Legros, MD, Joelle Guilhot, BS, Mauricette Michallet, MD, Francois Xavier Mahon, MD, Cecile Pautas, MD, Denis Guyotat, MD, Agnes Guerci, MD, Christian Berthou, MD, Bernard Rio, MD, Lydia Roy, MD, Patrice Berthaud, MD, Francois Guilhot, MD

Blood (2004) 104 (11): 1002.

https://doi.org/10.1182/blood.V104.11.1002.1002

Published: 2004

NARROW

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.

Results of a Phase II Trial Testing Interferon Alpha 2b and Cytarabine in Children with Chronic Myelogenous Leukemia.

A Phase I/II Dose Escalating Study of Daunorubicin Combined with Imatinib Mesylate and Cytarabine as Induction Therapy for Chronic Myelogenous Leukaemia in Myeloid Blast Crisis. Preliminary Results of the AFR01 Trial.

Email alerts

ASH Publications

American Society of Hematology

Imatinib Is Efficient but Has a Negative Impact On Growth in Children with Previously Untreated chronic Myelogenous Leukaemia (CML) in Early Chronic Phase (CP): Results of the French National Phase IV Trial.

Retrospective Comparison of Imatinib Versus Interferon Plus Cytarabine (IFN/Ara-c) for Chronic Myelogenous Leukemia (CML) Patients in Chronic Phase (CP).

Randomized Comparison of Imatinib with Imatinib Combination Therapies in Newly Diagnosed Chronic Myelogenous Leukemia Patients in Chronic Phase: Design and First Interim Analysis of a Phase III Trial from the French CML Group.

Results of a Phase II Trial Testing Interferon Alpha 2b and Cytarabine in Children with Chronic Myelogenous Leukemia.

A Phase I/II Dose Escalating Study of Daunorubicin Combined with Imatinib Mesylate and Cytarabine as Induction Therapy for Chronic Myelogenous Leukaemia in Myeloid Blast Crisis. Preliminary Results of the AFR01 Trial.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only